Negative influence of L-dopa on subjectively assessed sleep but not on nocturnal polysomnography in Parkinson's disease.
Journal Title: Pharmacological Reports - Year 2013, Vol 65, Issue 3
Abstract
Background: Sleep disorders are highly prevalent among patients with Parkinson's disease (PD). Chronic medication with L-dopa may be one of the factors that contributes to poor sleep quality. The aim of this study was to assess the effects of long term use of L-dopa on objective and subjective measures of sleep quality in PD patients. Methods: Twenty-seven PD patients (mean age 62.5 ± 8.6 years, mean disease duration 7.3 ± 5.9 years, 11 females) underwent nocturnal polysomnography. Their sleep was rated subjectively using the Parkinson's disease sleep scale (PDSS), and their disease severity was assessed using the unified Parkinson's disease severity scale (UPDRS) standard questionnaire. Doses of L-dopa and other medications were correlated with parameters of sleep quality. The polysomnographic recordings were compared with those from 24 age- and gender-matched normal controls. Results: The patients showed decreased total sleep time (TST) and sleep efficiency (SE), prolonged sleep onset and REM sleep latency and wake after sleep onset (WASO). Parts I-III of the UPDRS scores correlated with TST, SE and WASO but not with PDSS scores. L-dopa dosage and part IV of the UPDRS correlated with PDSS scores but not with polysomnographic parameters. Conclusions: Higher doses of chronically administered L-dopa correlated with lower sleep quality according to the subjective measures but not according to the polysomnographic parameters, which were related to the severity of PD symptoms. The low sleep quality according to the subjective measurements may result from complications of therapy at high doses of L-dopa.
Authors and Affiliations
Jakub Antczak, Maria Rakowicz, Marta Banach, Mirosława Derejko, Urszula Zalewska, Małgorzata Więcławska, Tomasz Jakubczyk, Wojciech Jernajczyk
Keywords
Related Articles
- EP ID EP87694
- DOI -
- Views 133
- Downloads 0
Theophylline, adenosine receptor antagonist prevents behavioral, biochemical and neurochemical changes associated with an animal model of tardive dyskinesia.
Tardive dyskinesia is considered to be the late onset adverse effect of prolonged administration of typical neuroleptic drugs. Adenosine is now widely accepted as the major inhibitory neuromodulators in the central nervo...
Serum and intraerythrocyte antioxidant enzymes and lipid peroxides in children with migraine.
The oxidant-antioxidant balance disorders underlie a number of acute and chronic diseases of the central nervous system (CNS). It is believed that oxidative stress plays a role in the pathogenesis of migraine. The study...
Effect of topiramate on hippocampus-dependent spatial memory in rats.
Background: Topiramate, a new generation antiepileptic agent with a complex mechanism of action, has a broad pharmacological profile which includes a neuroprotective effect. It has been proven to be efficacious in treati...
CPU0213, a novel endothelin receptor antagonist, suppresses the upregulation of matrix metalloproteinases and connexin 43 in hyperthyroid myocardium.
It has been verified that endothelin-1 (ET-1) activates matrix metalloproteinase (MMP) in the process of myocardial remodeling. Sustained high thyroid hormone level gives rise to left ventricular hypertrophy, in which th...
Plasma concentrations of adhesion molecules and chemokines in patients with essential hypertension.
Arterial hypertension vascular injury results in serious complications, such as left-ventricular hypertrophy and myocardial failure, ischemic heart disease and cerebral stroke. Currently, it is well known that inflammato...